NPHC NUTRA PHARMA CORP
Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1119643 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY-49.0%
TTM net income YoY-255.0%
TTM EPS YoY—
Revenue 3-yr CAGR-31.6%
Net income 3-yr CAGR—
Margins
Gross margin64.8%
Operating margin-1,017.8%
Net margin-3,370.6%
FCF margin—
EBITDA margin-1,011.4%
Returns
ROE—
ROA-731.5%
ROIC (approx.)—
Asset turnover0.22x
Leverage & solvency
Liabilities / assets3,505.0%
Debt / equity—
Current ratio0.02x
Interest coverage-68.24x
Cash quality & payout
Operating cash flow / net income0.19x
Accruals ratio-589.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $257,612 | $246,309 | $205,564 | $145,800 | $97,735 |
| Cost of revenue | $183,679 | $240,557 | $177,525 | $162,842 | $41,268 |
| Gross profit | $196,628 | $247,323 | $396,455 | $249,022 | $8,467 |
| SG&A expense | — | $1.13M | $1.18M | $2.08M | $1.93M |
| Operating income | -$1.46M | -$878,421 | -$886,979 | -$1.91M | -$1.99M |
| Interest expense | $22,870 | $21,237 | $18,815 | $17,141 | $18,246 |
| Pretax income | -$2.05M | -$1.29M | -$1.39M | $8.18M | -$13.10M |
| Net income | -$2.05M | -$1.29M | -$1.39M | $8.18M | -$13.10M |
| EBITDA | -$1.45M | -$870,981 | -$868,791 | -$1.88M | -$1.98M |
| EPS (basic) | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 |
| EPS (diluted) | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 |
| Weighted avg. shares (diluted) | 7.78B | 7.67B | 7.61B | 19.10B | 7.23B |
| Balance sheet | |||||
| Cash & equivalents | $12,181 | $36,447 | $0 | $0 | $90,910 |
| Short-term investments | $17,600 | $17,600 | $35,200 | — | — |
| Receivables | — | — | $22,433 | $21,664 | $45,998 |
| Inventory | $19,535 | $17,696 | $19,544 | $23,866 | $31,289 |
| Current assets | $459,583 | $374,837 | $314,060 | $333,577 | $533,827 |
| PP&E, net | $25,805 | $10,402 | $17,842 | $80,012 | $44,701 |
| Total assets | $622,601 | $599,495 | $640,397 | $754,913 | $780,022 |
| Current liabilities | $17.31M | $15.27M | $14.17M | $12.70M | $21.14M |
| Short-term debt | $9.62M | $8.49M | $8.33M | $7.93M | $7.60M |
| Long-term debt | $136,644 | $140,217 | $143,657 | $8.19M | — |
| Total debt | $9.76M | $8.63M | $8.47M | $16.12M | — |
| Total liabilities | $17.45M | $15.41M | $14.41M | $13.13M | $21.66M |
| Shareholders' equity | -$16.83M | -$14.81M | -$13.77M | -$12.38M | -$20.88M |
| Net debt | $9.75M | $8.59M | $8.47M | $16.12M | — |
| Shares outstanding | 7.10B | 7.10B | 7.06B | 7.04B | 6.77B |
| Cash flow statement | |||||
| Operating cash flow | -$1.16M | -$423,959 | -$550,036 | -$762,432 | -$1.74M |
| Capital expenditure | $26,052 | — | — | $57,993 | $39,043 |
| Free cash flow | -$1.19M | — | — | -$820,425 | -$1.78M |
| Investing cash flow | -$51,052 | $41,300 | $117,355 | $27,306 | -$293,543 |
| Financing cash flow | $1.19M | $419,106 | $432,681 | $644,216 | $2.13M |
| Depreciation & amortization | $10,649 | $7,440 | $18,188 | $22,682 | $9,084 |
| Stock-based compensation | $26,667 | — | — | $20,500 | $153,500 |
Free plan shows the latest 5 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.